Aflibercept in Diabetic Macular Oedema: Added Benefit Not Proven

Share this content:
Aflibercept in diabetic macular oedema: Added benefit not proven
Aflibercept in diabetic macular oedema: Added benefit not proven
Since August 2014, aflibercept (trade name Eylea) has been available also for patients with visual impairment due to diabetic macular oedema (DMO). The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy.
READ FULL ARTICLE From Medical Express
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




is free, fast, and customized just for you!




Already a member?

Sign In Now »